Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.

The potency of thrombin inhibition by 4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)-sulfony l]- L-arginyl]-2-piperidinecarboxylic acid (MQPA) depended on the stereoconformation of the 2-piperidinecarboxylic acid moiety. Ki values for bovine alpha-thrombin were 0.019 microM with (2R,4R)-MQPA, 0.24 microM with (2R,4S)-MQPA, 1.9 microM with (2S,4R)-MQPA, and 280 microM with (2S,4S)-MQPA. (2R,4R)-MQPA of the four stereoisomers of MQPA was also the most potent inhibitor for other trypsin-like serine proteases with Ki values of 5.0 microM for trypsin, 210 microM for factor Xa, 800 microM for plasmin, and 1500 microM for plasma kallikrein. Examination of the potency of thrombin inhibition by arginine derivatives related to MQPA in structure suggested the presence of a specific binding site for the carboxamide portion (C-terminal side). The relative inhibitory potency of the four stereoisomers of MQPA for trypsin was nearly identical with that for thrombin, suggesting that the specific binding site for the carboxamide portion is present in both enzymes. Modification of thrombin by phosphopyridoxylation or the presence of heparin did not significantly alter the binding of MQPA.

[1]  R. Parrish,et al.  Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives. , 1978, Journal of medicinal chemistry.

[2]  R. Tidwell,et al.  Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement. , 1976, Journal of medicinal chemistry.

[3]  R. Kikumoto,et al.  Thrombin inhibitors. 1. Ester derivatives of N alpha-(arylsulfonyl)-L-arginine. , 1980, Journal of medicinal chemistry.

[4]  H. Scheraga,et al.  Mechanism of action of thrombin on fibrinogen. Size of the A alpha fibrinogen-like peptide that contacts the active site of thrombin. , 1980, Biochemistry.

[5]  R. Kikumoto,et al.  Kinetic Studies on the Selectivity of a Synthetic Thrombin-Inhibitor Using Synthetic Peptide Substrates , 1979, Thrombosis and Haemostasis.

[6]  K. Mann,et al.  Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. , 1973, The Journal of biological chemistry.

[7]  M. Griffith.  Covalent modification of human alpha-thrombin with pyridoxal 5'-phosphate. Effect of phosphopyridoxylation on the interaction of thrombin with heparin. , 1979, The Journal of biological chemistry.

[8]  K. Mann,et al.  Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. , 1979, Biochemistry.

[9]  R. Colman,et al.  [25] Human kallikrein and prekallikrein , 1976 .

[10]  T. Tezuka,et al.  Thrombin inhibitors. 2. Amide derivatives of N alpha-substituted L-arginine. , 1980, Journal of medicinal chemistry.

[11]  W. Cleland,et al.  The statistical analysis of enzyme kinetic data. , 1967, Advances in enzymology and related areas of molecular biology.

[12]  T. Tezuka,et al.  Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N alpha-substituted L-arginine. , 1980, Journal of medicinal chemistry.

[13]  H. Kingdon,et al.  The interaction of heparin with human alpha-thrombin: effect on the hydrolysis of anilide tripeptide substrates. , 1979, Archives of biochemistry and biophysics.

[14]  R. Lundblad.  A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride. , 1971, Biochemistry.

[15]  H. Scheraga,et al.  Steady-state kinetic study of the bovine thrombin-fibrinogen interaction. , 1980, Biochemistry.

[16]  W. Leithe.  Die Konfiguration des optisch aktiven Coniins und α‐Pipecolins , 1932 .

[17]  R. Kikumoto,et al.  Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. , 1981, Biochemical and biophysical research communications.